Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) have earned an average recommendation of "Moderate Buy" from the six brokerages that are currently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $10.40.

A number of equities analysts have issued reports on IRWD shares. Leerink Partnrs raised shares of Ironwood Pharmaceuticals to a "hold" rating in a research note on Monday, September 9th. Craig Hallum dropped their price objective on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a "buy" rating for the company in a report on Friday, August 9th. StockNews.com lowered Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, November 12th. Wells Fargo & Company decreased their target price on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an "overweight" rating for the company in a research report on Friday, August 9th. Finally, Leerink Partners assumed coverage on Ironwood Pharmaceuticals in a research note on Monday, September 9th. They issued a "market perform" rating and a $5.00 price target for the company.

Insiders Place Their Bets

In other Ironwood Pharmaceuticals news, CFO Sravan Kumar Emany sold 11,001 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $4.08, for a total value of $44,884.08. Following the transaction, the chief financial officer now owns 309,572 shares of the company's stock, valued at approximately $1,263,053.76. The trade was a 3.43 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 12.90% of the company's stock.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Robeco Institutional Asset Management B.V. boosted its stake in Ironwood Pharmaceuticals by 1,293.6% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 380,960 shares of the biotechnology company's stock worth $1,570,000 after purchasing an additional 353,624 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Ironwood Pharmaceuticals by 150.7% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 126,289 shares of the biotechnology company's stock worth $520,000 after buying an additional 75,917 shares during the period. Pacer Advisors Inc. grew its holdings in shares of Ironwood Pharmaceuticals by 26.6% during the third quarter. Pacer Advisors Inc. now owns 11,279,822 shares of the biotechnology company's stock worth $46,473,000 after buying an additional 2,372,183 shares in the last quarter. KBC Group NV raised its position in Ironwood Pharmaceuticals by 59.3% in the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company's stock valued at $35,000 after buying an additional 3,198 shares during the last quarter. Finally, Hodges Capital Management Inc. lifted its stake in Ironwood Pharmaceuticals by 20.6% in the 2nd quarter. Hodges Capital Management Inc. now owns 1,041,000 shares of the biotechnology company's stock valued at $6,787,000 after acquiring an additional 177,500 shares in the last quarter.

Ironwood Pharmaceuticals Stock Performance

IRWD traded up $0.09 during mid-day trading on Friday, reaching $3.43. The stock had a trading volume of 2,952,910 shares, compared to its average volume of 1,532,075. The firm's fifty day simple moving average is $4.06 and its two-hundred day simple moving average is $5.08. The stock has a market capitalization of $548.90 million, a P/E ratio of -114.33 and a beta of 0.41. Ironwood Pharmaceuticals has a 52 week low of $3.06 and a 52 week high of $15.70.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 EPS for the quarter, missing analysts' consensus estimates of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The firm had revenue of $91.60 million during the quarter, compared to analyst estimates of $91.22 million. During the same quarter in the previous year, the business earned $0.12 earnings per share. Ironwood Pharmaceuticals's revenue for the quarter was down 19.4% compared to the same quarter last year. As a group, analysts expect that Ironwood Pharmaceuticals will post 0.08 EPS for the current fiscal year.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.